<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03205371</url>
  </required_header>
  <id_info>
    <org_study_id>MET57</org_study_id>
    <secondary_id>U1111-1161-2787</secondary_id>
    <nct_id>NCT03205371</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers</brief_title>
  <official_title>Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Other Pediatric Vaccines in Healthy Toddlers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase III, open-label, randomized, parallel-group, active-controlled, multicenter study
      was conducted to assess the immunogenicity and safety of a single dose of Meningococcal
      Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine when
      administered alone and in combination with other pediatric vaccines in healthy toddlers in
      South Korea, Thailand, the Russian Federation, and Mexico.

      Primary Objective:

        -  To describe the immunogenicity profile of MenACYW Conjugate vaccine administered alone
           or concomitantly with licensed pediatric vaccine(s) (measles-mumps-rubella vaccine [MMR]
           + Varicella, diphtheria, tetanus, acellular pertussis, hepatitis B, poliomyelitis, and
           Haemophilus influenzae type-b Conjugate vaccine [DTaP-IPV-HB-Hib], or pneumococcal
           Conjugate vaccine [PCV13]).

      Secondary Objective:

        -  To describe the immunogenicity profile of licensed pediatric vaccine(s) (MMR +
           Varicella, DTaP-IPV-HB-Hib, or PCV13) when administered alone or concomitantly with
           MenACYW Conjugate vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy, meningococcal-vaccine na√Øve toddlers aged 12 to 23 months were randomized either to
      a single dose of MenACYW Conjugate vaccine alone or in combination with other pediatric
      vaccines in healthy toddlers in South Korea and Thailand (MMR + varicella vaccine), the
      Russian Federation (PCV13), and Mexico (DTaP-IPV-HB-Hib). Immunogenicity (pre- and 30 days
      post-vaccination) and safety was assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2016</start_date>
  <completion_date type="Actual">July 19, 2018</completion_date>
  <primary_completion_date type="Actual">July 19, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase III, open-label, randomized, parallel-group, active-controlled, multicenter study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The study had an open-label design; however, as per the protocol, the laboratory technicians who were responsible for performing the serological testing remained blinded to the participants' group allocations throughout the study to avoid any bias.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers of Meningococcal Serogroups A, C, Y, and W Antibodies Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11</measure>
    <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
    <description>Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by serum bactericidal assay using human complement (hSBA) assay. Data for this outcome measure was planned to reported for the combined population of Groups 1 and 10, Groups 2 and 11.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Antibody Titers &gt;=1:4 and &gt;=1:8 Against Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11</measure>
    <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
    <description>Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With &gt;=4-Fold Rise in Antibody Titers Against Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11</measure>
    <time_frame>Day 0 up to Day 30 post-vaccination</time_frame>
    <description>Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11</measure>
    <time_frame>Day 30 post-vaccination</time_frame>
    <description>The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers &gt;=1:16 for participants with pre-vaccination titers &lt;1:8 or at least a 4-fold increase in post-vaccination hSBA titers from pre- to post-vaccination, for participants with pre-vaccination titers &gt;=1:8. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of MMR-Varicella Antibodies Following Injection With MMR-Varicella Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 1, 3, 10, and 12</measure>
    <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
    <description>Antibodies titers of Measles and Rubella were measured by enzyme immunoassay (EIA). Antibodies titers for mumps and varicella were measured by enzyme-linked immunosorbent assay (ELISA). Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 3 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Immune Response Following Injection With MMR-Varicella Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 1, 3, 10, and 12</measure>
    <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
    <description>Immune response for MMR-Varicella vaccine was defined as: anti-measles Antibody (Ab) concentrations &gt;=255 milli-international unit per milliliter (mIU/mL), anti-mumps Ab concentrations: &gt;=10 Ab units/mL, anti-rubella Ab concentrations &gt;=10 international unit per milliliter (IU/mL),anti-varicella Ab concentrations &gt;=5 glycoprotein enzyme-linked immunosorbent assay (gpELISA) Ab units/mL. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 3 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Pertussis Toxoid (PT) and Filamentous Hemagglutinin (FHA) Antibodies Following Injection With DTaP-IPV-HB-Hib Vaccine Administrated Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6</measure>
    <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
    <description>Antibodies titers of PT and FHA were measured by electrochemiluminescent (ECL) assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of DTaP-IPV-HB-Hib Antibodies Following Injection With DTaP-IPV-HB-Hib Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6</measure>
    <time_frame>Day 0 (for tetanus only) and Day 30 post-vaccination</time_frame>
    <description>Antibodies titers of Diphtheria, Tetanus and Pertussis were measured by ECL assay. Antibodies titers of poliovirus types 1, 2, and 3 were measured by neutralization assay. Antibodies titers of Hepatitis B were measured by an immunodiagnostic system using chemiluminescence detection. Antibodies titers of Polyribosyl-ribitol phosphate (PRP) were measured by Farr-type radioimmunoassay (RIA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Immune Response Following Injection With DTaP-IPV-HB-Hib Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6</measure>
    <time_frame>Day 0 (tetanus only) and Day 30 post-vaccination</time_frame>
    <description>Immune response for DTaP-IPV-HB-Hib vaccine was defined as: anti-tetanus Ab concentrations: &gt;= 0.01 and 0.1 IU/mL at Day 0 and &gt;= 0.1 and 1.0 IU/mL at Day 30, anti-diphtheria Ab concentrations: &gt;= 0.1 and 1.0 IU/mL, anti-PRP Ab concentrations &gt;= 0.15 and 1.0 microgram per milliliter (mcg/mL), anti-poliovirus types 1, 2, and 3 Ab titers &gt;= 1:8, anti-hepatitis B surface antigen Ab concentrations &gt;= 10 mIU/mL, &gt;= 100 mIU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Vaccine Response of PT and FHA Antibodies Following Injection With DTaP-IPV-HB-Hib Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6</measure>
    <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
    <description>Pertussis and FHA vaccine response was defined as: if the pre-vaccination concentration is &lt; 4 * lower limit of quantification (LLOQ is equal to 2), then the post-vaccination concentration is &gt;=4 * pre-vaccination concentration and if the pre-vaccination concentration is &gt;= 4 * LLOQ, then the post-vaccination concentration is &gt;= 2 * pre-vaccination concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of PCV13 Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F Antibodies Following Injection With PCV13 Vaccine Administrated Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 7 and 9</measure>
    <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
    <description>Antibodies of pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F were measured by ECL assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Immune Response Following Injection With PCV13 Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 7 and 9</measure>
    <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
    <description>Immune response for PCV13 for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F was defined as: antibodies concentrations &gt;=0.35 mcg/mL or &gt;=1.0 mcg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 1, 2, 3, 10, 11, and 12</measure>
    <time_frame>Within 7 days post vaccination</time_frame>
    <description>Solicited Reaction (SR) was defined as an adverse event (AE) that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved or the movement of the injected limb reduced, Erythema and swelling: Grade 3: &gt;= 50 millimeter (mm). Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 4, 5, and 6</measure>
    <time_frame>Within 7 days post vaccination</time_frame>
    <description>SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved or the movement of the injected limb reduced, Erythema and swelling: Grade 3: &gt;= 50 mm. Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 7, 8, and 9</measure>
    <time_frame>Within 7 days post vaccination</time_frame>
    <description>SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved, or the movement of the injected limb reduced, Erythema and swelling: Grade 3: &gt;= 50 mm. Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting at Least One Solicited Systemic Reactions (Fever, Vomiting, Abnormal Crying, Drowsiness, Appetite Loss, and Irritability)</measure>
    <time_frame>Within 7 days post vaccination</time_frame>
    <description>SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited systemic reaction: Fever: Grade 3: &gt; 39.5 degree Celsius, Vomiting: Grade 3: &gt;= 6 episodes per 24 hours or requiring parenteral hydration, Crying abnormal: Grade 3: &gt; 3 hours, Drowsiness: Grade 3: sleeping most of the time or difficult to wake up, Appetite lost: Grade 3: refuses &gt;= 3 feeds/meals or refuses most feeds/meals, Irritability: Grade 3: inconsolable. Participants with any of the Grade and Grade 3 solicited systemic reactions were reported.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">1183</enrollment>
  <condition>Meningitis, Meningococcal</condition>
  <arm_group>
    <arm_group_label>South Korea(Group1):MenACYW Conjugate + MMR+ Varicella Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>South Korea (Group 2): MenACYW Conjugate Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>South Korea (Group 3): MMR + Varicella Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thailand (Group 10):MenACYW Conjugate +MMR+Varicella Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thailand (Group 11):MenACYW Conjugate Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thailand (Group 12): MMR + Varicella Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and diphtheria, tetanus, acellular pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type-b (DTaP-IPV-HB-Hib) vaccine on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mexico (Group 5): MenACYW Conjugate Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of DTaP-IPV-HB-Hib vaccine on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate vaccine and pneumococcal Conjugate vaccine (PCV13) on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Russian Federation (Group 8): MenACYW Conjugate Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 14 months or 16 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Russian Federation (Group 9): PCV13 Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of PCV13 vaccine on Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACYW conjugate vaccine</intervention_name>
    <description>Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; 0.5 milliliter (mL), Intramuscular</description>
    <arm_group_label>Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine</arm_group_label>
    <arm_group_label>Mexico (Group 5): MenACYW Conjugate Vaccine</arm_group_label>
    <arm_group_label>Russian Federation (Group 8): MenACYW Conjugate Vaccine</arm_group_label>
    <arm_group_label>Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine</arm_group_label>
    <arm_group_label>South Korea (Group 2): MenACYW Conjugate Vaccine</arm_group_label>
    <arm_group_label>South Korea(Group1):MenACYW Conjugate + MMR+ Varicella Vaccine</arm_group_label>
    <arm_group_label>Thailand (Group 10):MenACYW Conjugate +MMR+Varicella Vaccine</arm_group_label>
    <arm_group_label>Thailand (Group 11):MenACYW Conjugate Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MMR</intervention_name>
    <description>Measles, Mumps, and Rubella Virus Vaccine Live; 0.5 mL, Subcutaneous</description>
    <arm_group_label>South Korea (Group 3): MMR + Varicella Vaccine</arm_group_label>
    <arm_group_label>South Korea(Group1):MenACYW Conjugate + MMR+ Varicella Vaccine</arm_group_label>
    <arm_group_label>Thailand (Group 10):MenACYW Conjugate +MMR+Varicella Vaccine</arm_group_label>
    <arm_group_label>Thailand (Group 12): MMR + Varicella Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Varicella</intervention_name>
    <description>Varicella Virus Vaccine Live; 0.5 mL, Subcutaneous</description>
    <arm_group_label>South Korea (Group 3): MMR + Varicella Vaccine</arm_group_label>
    <arm_group_label>South Korea(Group1):MenACYW Conjugate + MMR+ Varicella Vaccine</arm_group_label>
    <arm_group_label>Thailand (Group 10):MenACYW Conjugate +MMR+Varicella Vaccine</arm_group_label>
    <arm_group_label>Thailand (Group 12): MMR + Varicella Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV-HB-Hib</intervention_name>
    <description>Diphtheria, Tetanus, Pertussis (acellular component), Hepatitis B, Poliomyelitis (inactivated), and Haemophilus influenzae type-b conjugate vaccine (adsorbed); 0.5 mL, Intramuscular</description>
    <arm_group_label>Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine</arm_group_label>
    <arm_group_label>Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV13</intervention_name>
    <description>Pneumococcal 13-valent Conjugate Vaccine; 0.5 mL, Intramuscular</description>
    <arm_group_label>Russian Federation (Group 9): PCV13 Vaccine</arm_group_label>
    <arm_group_label>Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For South Korea: Korean males and females aged 12 to 23 months on the day of the first
             study visit.

          -  For Mexico: Males and females aged 12 to 23 months on the day of the first study
             visit.

          -  For the Russian Federation: Males and females aged 12 to 14 months or 16 to 23 months
             on the day of the first study visit (eligible for enrollment to MenACYW Conjugate
             vaccine group) or 15 to 23 months on the day of the first study visit (eligible for
             enrollment to the MenACYW Conjugate vaccine positive(+) PCV13 group or the PCV13
             group).

          -  For Thailand: Thai males and females aged 12 to 23 months on the day of the first
             study visit

          -  Participants had received all recommended standard of care vaccinations according to
             their age as per local regulations*.

          -  For the Russian Federation only, participants aged 15 to 23 months on the day of the
             first study visit (eligible for enrollment to MenACYW Conjugate vaccine+PCV13 group or
             the PCV13 group) must not had received the third PCV13 vaccination corresponding to
             his or her age as per the country's National Immunization Program (NIP). The 2nd dose
             of PCV13 must had been administered at least 4 weeks before the 3rd dose of PCV13 was
             administered in the study.

          -  For South Korea, participants must not had received the MMR or Varicella vaccination
             corresponding to his or her age at inclusion.

          -  For Mexico, participants must not had received the DTaP-IPV-HB-Hib vaccination
             corresponding to his or her age at inclusion.

          -  For Thailand, participants must not have received the any dose of MMR or V
             vaccination.

          -  Informed consent form was signed and dated by the parent(s) or guardian if allowed by
             local regulations (and by independent witnesses if required by local regulations)‚Ä†.

          -  Participant and parent/guardian were able to attend all scheduled visits and to comply
             with all trial procedures.

          -  *Participants must had received the total number of doses expected for each vaccine
             recommended for his/her age in the respective NIPs, but inclusion of participants with
             variations in the vaccine administration timeframes is considered acceptable if the
             total number of doses for the corresponding vaccines had been completed (e.g., in
             Mexico, 3 infant doses of the pentavalent vaccine must had been administered but the
             4th dose due in the 2nd year of life should not had been administered for participants
             to be included in the trial). For the Russian Federation only, participants that had
             not received a seasonal flu vaccination from 6 months of age according to the Russian
             NIP were still eligible to participate in this study. For Thailand only, participants
             who had received a vaccine ahead of the schedule can still be included in the study
             provided the first doses of MMR and Varicella vaccines have not been administered
             prior to inclusion.

          -  ‚Ä†In the Russian Federation, as per local regulations, only the participant's parent(s)
             are entitled to sign an informed consent form. A child under the responsibility of a
             guardian were not included in the study.

        Exclusion Criteria:

          -  Participation in the 4 weeks preceding the first trial vaccination or planned
             participation during the present trial period in another clinical trial investigating
             a vaccine, drug, medical device, or medical procedure.

          -  Receipt of any vaccine in the 4 weeks (28 days) preceding the first trial vaccination
             or planned receipt of any vaccine prior to Visit 2 except for influenza vaccination,
             which may be received at least 2 weeks before or after the study investigational
             vaccines. This exception includes monovalent pandemic influenza vaccines and
             multivalent influenza vaccines.

          -  Previous vaccination against meningococcal disease with either the trial vaccine or
             another vaccine (i.e., mono- or polyvalent, polysaccharide, or conjugate meningococcal
             vaccine containing serogroups A, C, Y, or W; or meningococcal B vaccine).

          -  For participants enrolled at sites in the Russian Federation: previous vaccination
             with the third dose of PCV13 in participants 15 to 23 months of age (eligible for
             MenACYW Conjugate vaccine+PCV13 group or the PCV13).

          -  For participants enrolled at sites in Mexico: known history of seizures, or
             uncontrolled neurologic disorder (including epilepsy); or encephalopathy of unknown
             etiology occurring within 7 days following previous vaccination with pertussis
             containing vaccine; previous vaccination with DTaP-IPV-HB-Hib or DTaP-containing
             vaccine at 12 to 23 months of age.

          -  For participants enrolled at sites in South Korea and Thailand: known history of
             seizures, cerebral injury, or encephalopathy; previous vaccination with MMR or
             Varicella at 12 to 23 months of age.

          -  Receipt of immune globulins, blood or blood-derived products in the past 3 months.

          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,
             within the preceding 6 months; or long-term systemic corticosteroid therapy
             (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).

          -  History of meningococcal infection, confirmed either clinically, serologically, or
             microbiologically.

          -  At high risk for meningococcal infection during the trial, according to the
             Investigator's judgment (specifically, but not limited to, participants with
             persistent complement deficiency, with anatomic or functional asplenia, or
             participants traveling to countries with high endemic or epidemic disease).

          -  Known systemic hypersensitivity to any of the vaccine components, or history of a
             life-threatening reaction to the vaccine(s) used in the trial or to a vaccine
             containing any of the same substances.

          -  Verbal report of thrombocytopenia, as reported by the parent/guardian,
             contraindicating intramuscular (IM) vaccination by the Investigator's judgment.

          -  Known bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding
             inclusion, contraindicating IM vaccination by the Investigator's judgment.

          -  Personal history of Guillain-Barr√© syndrome (GBS).

          -  Personal history of an Arthus-like reaction after vaccination with a tetanus
             toxoid-containing vaccine.

          -  Chronic illness that, in the opinion of the investigator, is at a stage where it might
             interfere with trial conduct or completion.

          -  For participants enrolled at sites in South Korea or Mexico and Thailand: Moderate or
             severe acute illness/infection (according to investigator's judgment) on the day of
             vaccination or febrile illness (temperature &gt;= 38.0 degree Celsius [¬∞C]). A
             prospective participant should not be included in the study until the condition has
             resolved or the febrile event has subsided.

          -  For participants enrolled at sites in the Russian Federation: Acute disease of any
             severity on the day of vaccination or febrile illness (axillary temperature &gt;=
             37.0¬∞C). A prospective participant should not be included in the study until the
             condition has resolved or the febrile event had subsided.

          -  Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first
             blood draw.

          -  Identified as a natural or adopted child of the Investigator or employee with direct
             involvement in the proposed study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Ansan</city>
        <zip>425-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anyang</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ilsan</city>
        <zip>10444</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <zip>400-700</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeju City</city>
        <zip>63241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>02053</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>100-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>132-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>139-709</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suwon-si</city>
        <zip>442-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>W≈ènju</city>
        <zip>162</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yangsan</city>
        <zip>626-770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Acapulco</city>
        <zip>39670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tlaltizapan</city>
        <zip>62770</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnaul</city>
        <zip>656054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan'</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnodar</city>
        <zip>350015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>119296</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murmansk</city>
        <zip>183031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <zip>630102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perm</city>
        <zip>614066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <zip>191025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <zip>197101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <zip>443079</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smolensk</city>
        <zip>214014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pathum Wan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rajthevi</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related info</description>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
    <description>Related info</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <results_first_submitted>May 20, 2020</results_first_submitted>
  <results_first_submitted_qc>May 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2020</results_first_posted>
  <disposition_first_submitted>July 17, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>July 17, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 18, 2019</disposition_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningitis</keyword>
  <keyword>Meningococcal Meningitis</keyword>
  <keyword>Meningococcal Infections</keyword>
  <keyword>MenACYW Conjugate vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT03205371/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT03205371/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were enrolled in South Korea, Mexico, the Russian Federation, and Thailand from 07 November 2016 to 13 June 2018.</recruitment_details>
      <pre_assignment_details>A total of 1183 participants were enrolled and randomized in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>South Korea(Group1):MenACYW Conjugate +MMR +Varicella Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine, measles-mumps-rubella (MMR) vaccine, and varicella vaccine on Day 0.</description>
        </group>
        <group group_id="P2">
          <title>South Korea (Group 2): MenACYW Conjugate Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
        </group>
        <group group_id="P3">
          <title>South Korea (Group 3): MMR + Varicella Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.</description>
        </group>
        <group group_id="P4">
          <title>Thailand (Group 10):MenACYW Conjugate + MMR+ Varicella Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.</description>
        </group>
        <group group_id="P5">
          <title>Thailand (Group 11): MenACYW Conjugate Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
        </group>
        <group group_id="P6">
          <title>Thailand (Group 12): MMR + Varicella Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.</description>
        </group>
        <group group_id="P7">
          <title>Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and diphtheria, tetanus, acellular pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type-b (DTaP-IPV-HB-Hib) vaccine on Day 0.</description>
        </group>
        <group group_id="P8">
          <title>Mexico (Group 5): MenACYW Conjugate Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
        </group>
        <group group_id="P9">
          <title>Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of DTaP-IPV-HB-Hib vaccine on Day 0.</description>
        </group>
        <group group_id="P10">
          <title>Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate and pneumococcal Conjugate vaccine (PCV13) on Day 0.</description>
        </group>
        <group group_id="P11">
          <title>Russian Federation (Group 8): MenACYW Conjugate Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 14 months or 16 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
        </group>
        <group group_id="P12">
          <title>Russian Federation (Group 9): PCV13 Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of PCV13 vaccine on Day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="86"/>
                <participants group_id="P5" count="42"/>
                <participants group_id="P6" count="42"/>
                <participants group_id="P7" count="200"/>
                <participants group_id="P8" count="100"/>
                <participants group_id="P9" count="100"/>
                <participants group_id="P10" count="200"/>
                <participants group_id="P11" count="100"/>
                <participants group_id="P12" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set (SafAS)</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="86"/>
                <participants group_id="P5" count="42"/>
                <participants group_id="P6" count="42"/>
                <participants group_id="P7" count="200"/>
                <participants group_id="P8" count="100"/>
                <participants group_id="P9" count="100"/>
                <participants group_id="P10" count="200"/>
                <participants group_id="P11" count="100"/>
                <participants group_id="P12" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per-protocol Analysis Set (PPAS)</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="85"/>
                <participants group_id="P5" count="42"/>
                <participants group_id="P6" count="42"/>
                <participants group_id="P7" count="155"/>
                <participants group_id="P8" count="79"/>
                <participants group_id="P9" count="68"/>
                <participants group_id="P10" count="196"/>
                <participants group_id="P11" count="96"/>
                <participants group_id="P12" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="86"/>
                <participants group_id="P5" count="42"/>
                <participants group_id="P6" count="42"/>
                <participants group_id="P7" count="190"/>
                <participants group_id="P8" count="97"/>
                <participants group_id="P9" count="95"/>
                <participants group_id="P10" count="200"/>
                <participants group_id="P11" count="100"/>
                <participants group_id="P12" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was performed on all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>South Korea(Group1):MenACYW Conjugate +MMR+ Varicella Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.</description>
        </group>
        <group group_id="B2">
          <title>South Korea (Group 2): MenACYW Conjugate Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
        </group>
        <group group_id="B3">
          <title>South Korea (Group 3): MMR + Varicella Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.</description>
        </group>
        <group group_id="B4">
          <title>Thailand (Group 10): MenACYW Conjugate + MMR+Varicella Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.</description>
        </group>
        <group group_id="B5">
          <title>Thailand (Group 11): MenACYW Conjugate Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
        </group>
        <group group_id="B6">
          <title>Thailand (Group 12): MMR + Varicella Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.</description>
        </group>
        <group group_id="B7">
          <title>Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and DTaP-IPV-HB-Hib vaccine on Day 0.</description>
        </group>
        <group group_id="B8">
          <title>Mexico (Group 5): MenACYW Conjugate Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
        </group>
        <group group_id="B9">
          <title>Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of DTaP-IPV-HB-Hib vaccine on Day 0.</description>
        </group>
        <group group_id="B10">
          <title>Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate vaccine and pneumococcal Conjugate vaccine (PCV13) on Day 0.</description>
        </group>
        <group group_id="B11">
          <title>Russian Federation (Group 8): MenACYW Conjugate Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 14 months or 16 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
        </group>
        <group group_id="B12">
          <title>Russian Federation (Group 9): PCV13 Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of PCV13 vaccine on Day 0.</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="107"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="53"/>
            <count group_id="B4" value="86"/>
            <count group_id="B5" value="42"/>
            <count group_id="B6" value="42"/>
            <count group_id="B7" value="200"/>
            <count group_id="B8" value="100"/>
            <count group_id="B9" value="100"/>
            <count group_id="B10" value="200"/>
            <count group_id="B11" value="100"/>
            <count group_id="B12" value="100"/>
            <count group_id="B13" value="1183"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.7" spread="1.58"/>
                    <measurement group_id="B2" value="12.7" spread="1.50"/>
                    <measurement group_id="B3" value="12.3" spread="0.96"/>
                    <measurement group_id="B4" value="12.4" spread="0.90"/>
                    <measurement group_id="B5" value="12.4" spread="0.88"/>
                    <measurement group_id="B6" value="12.8" spread="1.76"/>
                    <measurement group_id="B7" value="16.4" spread="2.73"/>
                    <measurement group_id="B8" value="16.8" spread="2.83"/>
                    <measurement group_id="B9" value="16.8" spread="2.99"/>
                    <measurement group_id="B10" value="16.5" spread="2.36"/>
                    <measurement group_id="B11" value="16.0" spread="3.10"/>
                    <measurement group_id="B12" value="16.3" spread="2.26"/>
                    <measurement group_id="B13" value="15.2" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="93"/>
                    <measurement group_id="B8" value="46"/>
                    <measurement group_id="B9" value="48"/>
                    <measurement group_id="B10" value="78"/>
                    <measurement group_id="B11" value="51"/>
                    <measurement group_id="B12" value="45"/>
                    <measurement group_id="B13" value="550"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="107"/>
                    <measurement group_id="B8" value="54"/>
                    <measurement group_id="B9" value="52"/>
                    <measurement group_id="B10" value="122"/>
                    <measurement group_id="B11" value="49"/>
                    <measurement group_id="B12" value="55"/>
                    <measurement group_id="B13" value="633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="86"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="179"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="200"/>
                    <measurement group_id="B8" value="100"/>
                    <measurement group_id="B9" value="99"/>
                    <measurement group_id="B10" value="198"/>
                    <measurement group_id="B11" value="99"/>
                    <measurement group_id="B12" value="96"/>
                    <measurement group_id="B13" value="792"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="200"/>
                    <measurement group_id="B8" value="100"/>
                    <measurement group_id="B9" value="100"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="200"/>
                    <measurement group_id="B11" value="100"/>
                    <measurement group_id="B12" value="100"/>
                    <measurement group_id="B13" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="86"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers of Meningococcal Serogroups A, C, Y, and W Antibodies Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11</title>
        <description>Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by serum bactericidal assay using human complement (hSBA) assay. Data for this outcome measure was planned to reported for the combined population of Groups 1 and 10, Groups 2 and 11.</description>
        <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
        <population>Analysis was performed on PPAS which included participants who received at least one dose of the study vaccine(s), had a valid post-vaccination blood sample result and no protocol deviations. Data for this outcome measure were not planned to be collected and analyzed for Groups 3, 6, 9, and 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Groups 1and10: MenACYW Conjugate Vaccine+MMR+Varicella Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) from South Korea and Thailand received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Groups 2 and 11: MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) from South Korea and Thailand received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and DTaP-IPV-HB-Hib vaccine on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Mexico (Group 5): MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Russian Federation (Group 7): MenACYW Conjugate +PCV13 Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate vaccine and PCV13 vaccine on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>Russian Federation (Group 8): MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 14 months or 16 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Meningococcal Serogroups A, C, Y, and W Antibodies Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11</title>
          <description>Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by serum bactericidal assay using human complement (hSBA) assay. Data for this outcome measure was planned to reported for the combined population of Groups 1 and 10, Groups 2 and 11.</description>
          <population>Analysis was performed on PPAS which included participants who received at least one dose of the study vaccine(s), had a valid post-vaccination blood sample result and no protocol deviations. Data for this outcome measure were not planned to be collected and analyzed for Groups 3, 6, 9, and 12.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="155"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="196"/>
                <count group_id="O6" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.20" lower_limit="4.56" upper_limit="5.93"/>
                    <measurement group_id="O2" value="6.10" lower_limit="5.00" upper_limit="7.44"/>
                    <measurement group_id="O3" value="5.35" lower_limit="4.82" upper_limit="5.94"/>
                    <measurement group_id="O4" value="5.49" lower_limit="4.66" upper_limit="6.45"/>
                    <measurement group_id="O5" value="5.99" lower_limit="5.30" upper_limit="6.76"/>
                    <measurement group_id="O6" value="8.54" lower_limit="6.47" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A: Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9" lower_limit="37.4" upper_limit="51.6"/>
                    <measurement group_id="O2" value="30.0" lower_limit="23.1" upper_limit="39.0"/>
                    <measurement group_id="O3" value="31.4" lower_limit="25.9" upper_limit="38.1"/>
                    <measurement group_id="O4" value="37.8" lower_limit="28.5" upper_limit="50.2"/>
                    <measurement group_id="O5" value="24.6" lower_limit="20.2" upper_limit="30.1"/>
                    <measurement group_id="O6" value="49.0" lower_limit="36.8" upper_limit="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" lower_limit="2.11" upper_limit="2.65"/>
                    <measurement group_id="O2" value="2.58" lower_limit="2.15" upper_limit="3.10"/>
                    <measurement group_id="O3" value="2.21" lower_limit="2.11" upper_limit="2.31"/>
                    <measurement group_id="O4" value="2.16" lower_limit="2.00" upper_limit="2.34"/>
                    <measurement group_id="O5" value="2.77" lower_limit="2.43" upper_limit="3.16"/>
                    <measurement group_id="O6" value="3.69" lower_limit="2.84" upper_limit="4.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C: Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="876" lower_limit="725" upper_limit="1057"/>
                    <measurement group_id="O2" value="600" lower_limit="456" upper_limit="790"/>
                    <measurement group_id="O3" value="749" lower_limit="633" upper_limit="886"/>
                    <measurement group_id="O4" value="666" lower_limit="538" upper_limit="825"/>
                    <measurement group_id="O5" value="205" lower_limit="156" upper_limit="269"/>
                    <measurement group_id="O6" value="309" lower_limit="218" upper_limit="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.14" lower_limit="2.78" upper_limit="3.54"/>
                    <measurement group_id="O2" value="3.12" lower_limit="2.58" upper_limit="3.78"/>
                    <measurement group_id="O3" value="2.63" lower_limit="2.37" upper_limit="2.92"/>
                    <measurement group_id="O4" value="2.94" lower_limit="2.45" upper_limit="3.53"/>
                    <measurement group_id="O5" value="2.90" lower_limit="2.56" upper_limit="3.28"/>
                    <measurement group_id="O6" value="3.49" lower_limit="2.68" upper_limit="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y: Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="75.1" upper_limit="105"/>
                    <measurement group_id="O2" value="60.0" lower_limit="47.3" upper_limit="76.3"/>
                    <measurement group_id="O3" value="79.7" lower_limit="65.7" upper_limit="96.6"/>
                    <measurement group_id="O4" value="90.9" lower_limit="66.8" upper_limit="124"/>
                    <measurement group_id="O5" value="139" lower_limit="111" upper_limit="173"/>
                    <measurement group_id="O6" value="172" lower_limit="130" upper_limit="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" lower_limit="2.00" upper_limit="2.30"/>
                    <measurement group_id="O2" value="2.31" lower_limit="2.02" upper_limit="2.64"/>
                    <measurement group_id="O3" value="2.41" lower_limit="2.22" upper_limit="2.62"/>
                    <measurement group_id="O4" value="2.16" lower_limit="2.04" upper_limit="2.30"/>
                    <measurement group_id="O5" value="2.93" lower_limit="2.54" upper_limit="3.38"/>
                    <measurement group_id="O6" value="3.62" lower_limit="2.73" upper_limit="4.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W: Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.8" lower_limit="39.1" upper_limit="56.0"/>
                    <measurement group_id="O2" value="35.5" lower_limit="27.6" upper_limit="45.7"/>
                    <measurement group_id="O3" value="40.0" lower_limit="32.5" upper_limit="49.3"/>
                    <measurement group_id="O4" value="50.9" lower_limit="37.2" upper_limit="69.8"/>
                    <measurement group_id="O5" value="57.4" lower_limit="47.9" upper_limit="68.6"/>
                    <measurement group_id="O6" value="57.0" lower_limit="44.3" upper_limit="73.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Antibody Titers &gt;=1:4 and &gt;=1:8 Against Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11</title>
        <description>Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.</description>
        <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
        <population>Analysis was performed on PPAS. Data for this outcome measure were not planned to be collected and analyzed for Groups 3, 6, 9, and 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Groups 1and 10:MenACYW Conjugate Vaccine+MMR+Varicella Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) from South Korea and Thailand received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Groups 2 and 11: MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) from South Korea and Thailand received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and DTaP-IPV-HB-Hib vaccine on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Mexico (Group 5): MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Russian Federation (Group 7): MenACYW Conjugate +PCV13 Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate vaccine and PCV13 vaccine on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>Russian Federation (Group 8): MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 14 months or 16 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Antibody Titers &gt;=1:4 and &gt;=1:8 Against Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11</title>
          <description>Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.</description>
          <population>Analysis was performed on PPAS. Data for this outcome measure were not planned to be collected and analyzed for Groups 3, 6, 9, and 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="155"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="196"/>
                <count group_id="O6" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A: Day 0 (&gt;=1:4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" lower_limit="68.1" upper_limit="81.3"/>
                    <measurement group_id="O2" value="82.8" lower_limit="73.2" upper_limit="90.0"/>
                    <measurement group_id="O3" value="82.6" lower_limit="75.7" upper_limit="88.2"/>
                    <measurement group_id="O4" value="82.3" lower_limit="72.1" upper_limit="90.0"/>
                    <measurement group_id="O5" value="82.1" lower_limit="76.1" upper_limit="87.2"/>
                    <measurement group_id="O6" value="85.4" lower_limit="76.7" upper_limit="91.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A: Day 0 (&gt;=1:8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9" lower_limit="30.7" upper_limit="45.4"/>
                    <measurement group_id="O2" value="44.8" lower_limit="34.1" upper_limit="55.9"/>
                    <measurement group_id="O3" value="45.8" lower_limit="37.8" upper_limit="54.0"/>
                    <measurement group_id="O4" value="46.8" lower_limit="35.5" upper_limit="58.4"/>
                    <measurement group_id="O5" value="49.0" lower_limit="41.8" upper_limit="56.2"/>
                    <measurement group_id="O6" value="54.2" lower_limit="43.7" upper_limit="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A: Day 30 (&gt;=1:4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="96.0" upper_limit="99.9"/>
                    <measurement group_id="O2" value="95.4" lower_limit="88.6" upper_limit="98.7"/>
                    <measurement group_id="O3" value="98.1" lower_limit="94.4" upper_limit="99.6"/>
                    <measurement group_id="O4" value="97.5" lower_limit="91.2" upper_limit="99.7"/>
                    <measurement group_id="O5" value="94.9" lower_limit="90.8" upper_limit="97.5"/>
                    <measurement group_id="O6" value="97.9" lower_limit="92.7" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A: Day 30 (&gt;=1:8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="94.3" upper_limit="99.4"/>
                    <measurement group_id="O2" value="92.0" lower_limit="84.1" upper_limit="96.7"/>
                    <measurement group_id="O3" value="92.9" lower_limit="87.7" upper_limit="96.4"/>
                    <measurement group_id="O4" value="89.9" lower_limit="81.0" upper_limit="95.5"/>
                    <measurement group_id="O5" value="83.7" lower_limit="77.7" upper_limit="88.6"/>
                    <measurement group_id="O6" value="90.6" lower_limit="82.9" upper_limit="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C: Day 0 (&gt;=1:4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="5.7" upper_limit="14.9"/>
                    <measurement group_id="O2" value="16.1" lower_limit="9.1" upper_limit="25.5"/>
                    <measurement group_id="O3" value="12.3" lower_limit="7.5" upper_limit="18.5"/>
                    <measurement group_id="O4" value="7.6" lower_limit="2.8" upper_limit="15.8"/>
                    <measurement group_id="O5" value="19.9" lower_limit="14.5" upper_limit="26.2"/>
                    <measurement group_id="O6" value="36.5" lower_limit="26.9" upper_limit="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C: Day 0 (&gt;=1:8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.6" upper_limit="8.0"/>
                    <measurement group_id="O2" value="6.9" lower_limit="2.6" upper_limit="14.4"/>
                    <measurement group_id="O3" value="1.9" lower_limit="0.4" upper_limit="5.6"/>
                    <measurement group_id="O4" value="1.3" lower_limit="0.0" upper_limit="6.9"/>
                    <measurement group_id="O5" value="8.7" lower_limit="5.1" upper_limit="13.5"/>
                    <measurement group_id="O6" value="17.7" lower_limit="10.7" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C: Day 30 (&gt;=1:4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="95.4" upper_limit="100.0"/>
                    <measurement group_id="O5" value="98.5" lower_limit="95.6" upper_limit="99.7"/>
                    <measurement group_id="O6" value="99.0" lower_limit="94.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C: Day 30 (&gt;=1:8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="95.4" upper_limit="100.0"/>
                    <measurement group_id="O5" value="93.9" lower_limit="89.5" upper_limit="96.8"/>
                    <measurement group_id="O6" value="99.0" lower_limit="94.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y: Day 0 (&gt;=1:4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2" lower_limit="25.4" upper_limit="39.6"/>
                    <measurement group_id="O2" value="28.7" lower_limit="19.5" upper_limit="39.4"/>
                    <measurement group_id="O3" value="19.4" lower_limit="13.5" upper_limit="26.5"/>
                    <measurement group_id="O4" value="25.3" lower_limit="16.2" upper_limit="36.4"/>
                    <measurement group_id="O5" value="21.9" lower_limit="16.4" upper_limit="28.4"/>
                    <measurement group_id="O6" value="32.3" lower_limit="23.1" upper_limit="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y: Day 0 (&gt;=1:8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="13.2" upper_limit="25.2"/>
                    <measurement group_id="O2" value="17.2" lower_limit="10.0" upper_limit="26.8"/>
                    <measurement group_id="O3" value="11.0" lower_limit="6.5" upper_limit="17.0"/>
                    <measurement group_id="O4" value="12.7" lower_limit="6.2" upper_limit="22.0"/>
                    <measurement group_id="O5" value="14.3" lower_limit="9.7" upper_limit="20.0"/>
                    <measurement group_id="O6" value="15.6" lower_limit="9.0" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y: Day 30 (&gt;=1:4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="96.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96.6" lower_limit="90.3" upper_limit="99.3"/>
                    <measurement group_id="O3" value="98.7" lower_limit="95.4" upper_limit="99.8"/>
                    <measurement group_id="O4" value="100.0" lower_limit="95.4" upper_limit="100.0"/>
                    <measurement group_id="O5" value="98.5" lower_limit="95.6" upper_limit="99.7"/>
                    <measurement group_id="O6" value="99.0" lower_limit="94.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y: Day 30 (&gt;=1:8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="96.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="95.4" lower_limit="88.6" upper_limit="98.7"/>
                    <measurement group_id="O3" value="98.7" lower_limit="95.4" upper_limit="99.8"/>
                    <measurement group_id="O4" value="98.7" lower_limit="93.1" upper_limit="100.0"/>
                    <measurement group_id="O5" value="97.4" lower_limit="94.1" upper_limit="99.2"/>
                    <measurement group_id="O6" value="97.9" lower_limit="92.7" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W: Day 0 (&gt;=1:4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="2.4" upper_limit="9.4"/>
                    <measurement group_id="O2" value="11.5" lower_limit="5.7" upper_limit="20.1"/>
                    <measurement group_id="O3" value="14.8" lower_limit="9.6" upper_limit="21.4"/>
                    <measurement group_id="O4" value="8.9" lower_limit="3.6" upper_limit="17.4"/>
                    <measurement group_id="O5" value="16.8" lower_limit="11.9" upper_limit="22.8"/>
                    <measurement group_id="O6" value="26.0" lower_limit="17.6" upper_limit="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W: Day 0 (&gt;=1:8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.1" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.3" upper_limit="8.1"/>
                    <measurement group_id="O3" value="7.7" lower_limit="4.1" upper_limit="13.1"/>
                    <measurement group_id="O4" value="2.5" lower_limit="0.3" upper_limit="8.8"/>
                    <measurement group_id="O5" value="12.8" lower_limit="8.4" upper_limit="18.3"/>
                    <measurement group_id="O6" value="20.8" lower_limit="13.2" upper_limit="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W: Day 30 (&gt;=1:4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="96.0" upper_limit="99.9"/>
                    <measurement group_id="O2" value="96.6" lower_limit="90.3" upper_limit="99.3"/>
                    <measurement group_id="O3" value="97.4" lower_limit="93.5" upper_limit="99.3"/>
                    <measurement group_id="O4" value="96.2" lower_limit="89.3" upper_limit="99.2"/>
                    <measurement group_id="O5" value="95.9" lower_limit="92.1" upper_limit="98.2"/>
                    <measurement group_id="O6" value="96.9" lower_limit="91.1" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W: Day 30 (&gt;=1:8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="92.0" upper_limit="98.4"/>
                    <measurement group_id="O2" value="92.0" lower_limit="84.1" upper_limit="96.7"/>
                    <measurement group_id="O3" value="90.3" lower_limit="84.5" upper_limit="94.5"/>
                    <measurement group_id="O4" value="92.4" lower_limit="84.2" upper_limit="97.2"/>
                    <measurement group_id="O5" value="94.4" lower_limit="90.2" upper_limit="97.2"/>
                    <measurement group_id="O6" value="95.8" lower_limit="89.7" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With &gt;=4-Fold Rise in Antibody Titers Against Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11</title>
        <description>Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.</description>
        <time_frame>Day 0 up to Day 30 post-vaccination</time_frame>
        <population>Analysis was performed on PPAS. Data for this outcome measure were not planned to be collected and analyzed for Groups 3, 6, 9, and 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Groups 1 and10:MenACYW Conjugate Vaccine+MMR+Varicella Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) from South Korea and Thailand received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Groups 2 and 11: MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) from South Korea and Thailand received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and DTaP-IPV-HB-Hib vaccine on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Mexico (Group 5): MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Russian Federation (Group 7): MenACYW Conjugate +PCV13 Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate and PCV13 vaccine on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>Russian Federation (Group 8): MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 14 months or 16 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With &gt;=4-Fold Rise in Antibody Titers Against Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11</title>
          <description>Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.</description>
          <population>Analysis was performed on PPAS. Data for this outcome measure were not planned to be collected and analyzed for Groups 3, 6, 9, and 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="155"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="196"/>
                <count group_id="O6" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.5" lower_limit="76.1" upper_limit="87.8"/>
                    <measurement group_id="O2" value="64.4" lower_limit="53.4" upper_limit="74.4"/>
                    <measurement group_id="O3" value="69.0" lower_limit="61.1" upper_limit="76.2"/>
                    <measurement group_id="O4" value="70.9" lower_limit="59.6" upper_limit="80.6"/>
                    <measurement group_id="O5" value="58.2" lower_limit="50.9" upper_limit="65.2"/>
                    <measurement group_id="O6" value="72.9" lower_limit="62.9" upper_limit="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="95.1" upper_limit="99.6"/>
                    <measurement group_id="O2" value="98.9" lower_limit="93.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O4" value="98.7" lower_limit="93.1" upper_limit="100.0"/>
                    <measurement group_id="O5" value="92.3" lower_limit="87.7" upper_limit="95.7"/>
                    <measurement group_id="O6" value="91.7" lower_limit="84.2" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" lower_limit="91.3" upper_limit="98.0"/>
                    <measurement group_id="O2" value="89.7" lower_limit="81.3" upper_limit="95.2"/>
                    <measurement group_id="O3" value="96.8" lower_limit="92.6" upper_limit="98.9"/>
                    <measurement group_id="O4" value="94.9" lower_limit="87.5" upper_limit="98.6"/>
                    <measurement group_id="O5" value="94.4" lower_limit="90.2" upper_limit="97.2"/>
                    <measurement group_id="O6" value="93.8" lower_limit="86.9" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="90.6" upper_limit="97.6"/>
                    <measurement group_id="O2" value="89.7" lower_limit="81.3" upper_limit="95.2"/>
                    <measurement group_id="O3" value="86.5" lower_limit="80.0" upper_limit="91.4"/>
                    <measurement group_id="O4" value="92.4" lower_limit="84.2" upper_limit="97.2"/>
                    <measurement group_id="O5" value="88.8" lower_limit="83.5" upper_limit="92.8"/>
                    <measurement group_id="O6" value="90.6" lower_limit="82.9" upper_limit="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11</title>
        <description>The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers &gt;=1:16 for participants with pre-vaccination titers &lt;1:8 or at least a 4-fold increase in post-vaccination hSBA titers from pre- to post-vaccination, for participants with pre-vaccination titers &gt;=1:8. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.</description>
        <time_frame>Day 30 post-vaccination</time_frame>
        <population>Analysis was performed on PPAS. Data for this outcome measure were not planned to be collected and analyzed for Groups 3, 6, 9 and 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Groups 1 and10:MenACYW Conjugate Vaccine+MMR+Varicella Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) from South Korea and Thailand received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Groups 2 and 11: MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) from South Korea and Thailand received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and DTaP-IPV-HB-Hib vaccine on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Mexico (Group 5): MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Russian Federation (Group 7): MenACYW Conjugate +PCV13 Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate and PCV13 vaccine on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>Russian Federation (Group 8): MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 14 months or 16 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11</title>
          <description>The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers &gt;=1:16 for participants with pre-vaccination titers &lt;1:8 or at least a 4-fold increase in post-vaccination hSBA titers from pre- to post-vaccination, for participants with pre-vaccination titers &gt;=1:8. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.</description>
          <population>Analysis was performed on PPAS. Data for this outcome measure were not planned to be collected and analyzed for Groups 3, 6, 9 and 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="155"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="196"/>
                <count group_id="O6" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" lower_limit="71.7" upper_limit="84.3"/>
                    <measurement group_id="O2" value="63.2" lower_limit="52.2" upper_limit="73.3"/>
                    <measurement group_id="O3" value="67.1" lower_limit="59.1" upper_limit="74.4"/>
                    <measurement group_id="O4" value="69.6" lower_limit="58.2" upper_limit="79.5"/>
                    <measurement group_id="O5" value="56.1" lower_limit="48.9" upper_limit="63.2"/>
                    <measurement group_id="O6" value="71.9" lower_limit="61.8" upper_limit="80.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="94.3" upper_limit="99.4"/>
                    <measurement group_id="O2" value="98.9" lower_limit="93.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.6" upper_limit="100"/>
                    <measurement group_id="O4" value="98.7" lower_limit="93.1" upper_limit="100.0"/>
                    <measurement group_id="O5" value="90.8" lower_limit="85.9" upper_limit="94.5"/>
                    <measurement group_id="O6" value="91.7" lower_limit="84.2" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.2" lower_limit="88.5" upper_limit="96.4"/>
                    <measurement group_id="O2" value="88.5" lower_limit="79.9" upper_limit="94.3"/>
                    <measurement group_id="O3" value="92.3" lower_limit="86.9" upper_limit="95.9"/>
                    <measurement group_id="O4" value="87.3" lower_limit="78.0" upper_limit="93.8"/>
                    <measurement group_id="O5" value="92.9" lower_limit="88.3" upper_limit="96.0"/>
                    <measurement group_id="O6" value="92.7" lower_limit="85.6" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" lower_limit="80.5" upper_limit="91.1"/>
                    <measurement group_id="O2" value="83.9" lower_limit="74.5" upper_limit="90.9"/>
                    <measurement group_id="O3" value="82.6" lower_limit="75.7" upper_limit="88.2"/>
                    <measurement group_id="O4" value="82.3" lower_limit="72.1" upper_limit="90.0"/>
                    <measurement group_id="O5" value="82.1" lower_limit="76.1" upper_limit="87.2"/>
                    <measurement group_id="O6" value="90.6" lower_limit="82.9" upper_limit="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of MMR-Varicella Antibodies Following Injection With MMR-Varicella Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 1, 3, 10, and 12</title>
        <description>Antibodies titers of Measles and Rubella were measured by enzyme immunoassay (EIA). Antibodies titers for mumps and varicella were measured by enzyme-linked immunosorbent assay (ELISA). Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 3 and 12.</description>
        <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
        <population>Analysis was performed on PPAS. Here, ‚ÄòNumber analyzed‚Äô = participants with available data for each specified category. Data for this outcome measure were not planned to be collected and analyzed for Groups 2, 4, 5, 6, 7, 8, 9, and 11.</population>
        <group_list>
          <group group_id="O1">
            <title>Groups 1 and10:MenACYW Conjugate Vaccine+MMR+Varicella Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) from South Korea and Thailand received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Groups 3 and 12: MMR + Varicella Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) from South Korea and Thailand received single dose of MMR vaccine and varicella vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of MMR-Varicella Antibodies Following Injection With MMR-Varicella Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 1, 3, 10, and 12</title>
          <description>Antibodies titers of Measles and Rubella were measured by enzyme immunoassay (EIA). Antibodies titers for mumps and varicella were measured by enzyme-linked immunosorbent assay (ELISA). Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 3 and 12.</description>
          <population>Analysis was performed on PPAS. Here, ‚ÄòNumber analyzed‚Äô = participants with available data for each specified category. Data for this outcome measure were not planned to be collected and analyzed for Groups 2, 4, 5, 6, 7, 8, 9, and 11.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Measles: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="37.2" upper_limit="43.1"/>
                    <measurement group_id="O2" value="45.0" lower_limit="40.1" upper_limit="50.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2156" lower_limit="1893" upper_limit="2455"/>
                    <measurement group_id="O2" value="2840" lower_limit="2389" upper_limit="3378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.51" lower_limit="5.20" upper_limit="5.84"/>
                    <measurement group_id="O2" value="5.43" lower_limit="5.05" upper_limit="5.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.9" lower_limit="74.7" upper_limit="98.7"/>
                    <measurement group_id="O2" value="97.6" lower_limit="83.1" upper_limit="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.94" lower_limit="5.32" upper_limit="6.63"/>
                    <measurement group_id="O2" value="7.12" lower_limit="6.07" upper_limit="8.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.6" lower_limit="79.4" upper_limit="96.7"/>
                    <measurement group_id="O2" value="104" lower_limit="91.2" upper_limit="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.556" lower_limit="0.484" upper_limit="0.638"/>
                    <measurement group_id="O2" value="0.665" lower_limit="0.508" upper_limit="0.869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="11.6" upper_limit="15.4"/>
                    <measurement group_id="O2" value="17.4" lower_limit="15.2" upper_limit="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Immune Response Following Injection With MMR-Varicella Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 1, 3, 10, and 12</title>
        <description>Immune response for MMR-Varicella vaccine was defined as: anti-measles Antibody (Ab) concentrations &gt;=255 milli-international unit per milliliter (mIU/mL), anti-mumps Ab concentrations: &gt;=10 Ab units/mL, anti-rubella Ab concentrations &gt;=10 international unit per milliliter (IU/mL),anti-varicella Ab concentrations &gt;=5 glycoprotein enzyme-linked immunosorbent assay (gpELISA) Ab units/mL. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 3 and 12.</description>
        <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
        <population>Analysis was performed on PPAS. Here, ‚ÄòNumber analyzed‚Äô = participants with available data for each specified category. Data for this outcome measure were not planned to be collected and analyzed for Groups 2, 4, 5, 6, 7, 8, 9, and 11.</population>
        <group_list>
          <group group_id="O1">
            <title>Groups 1 and10:MenACYW Conjugate Vaccine+MMR+Varicella Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) from South Korea and Thailand received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Groups 3 and 12: MMR + Varicella Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) from South Korea and Thailand received single dose of MMR vaccine and varicella vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Immune Response Following Injection With MMR-Varicella Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 1, 3, 10, and 12</title>
          <description>Immune response for MMR-Varicella vaccine was defined as: anti-measles Antibody (Ab) concentrations &gt;=255 milli-international unit per milliliter (mIU/mL), anti-mumps Ab concentrations: &gt;=10 Ab units/mL, anti-rubella Ab concentrations &gt;=10 international unit per milliliter (IU/mL),anti-varicella Ab concentrations &gt;=5 glycoprotein enzyme-linked immunosorbent assay (gpELISA) Ab units/mL. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 3 and 12.</description>
          <population>Analysis was performed on PPAS. Here, ‚ÄòNumber analyzed‚Äô = participants with available data for each specified category. Data for this outcome measure were not planned to be collected and analyzed for Groups 2, 4, 5, 6, 7, 8, 9, and 11.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Measles: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.0" upper_limit="3.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" lower_limit="92.8" upper_limit="98.7"/>
                    <measurement group_id="O2" value="97.8" lower_limit="92.4" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="4.0" upper_limit="12.3"/>
                    <measurement group_id="O2" value="6.5" lower_limit="2.4" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="94.3" upper_limit="99.4"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" lower_limit="20.8" upper_limit="34.5"/>
                    <measurement group_id="O2" value="31.5" lower_limit="22.2" upper_limit="42.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.6" upper_limit="8.0"/>
                    <measurement group_id="O2" value="7.6" lower_limit="3.1" upper_limit="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.2" lower_limit="88.5" upper_limit="96.4"/>
                    <measurement group_id="O2" value="98.9" lower_limit="94.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Pertussis Toxoid (PT) and Filamentous Hemagglutinin (FHA) Antibodies Following Injection With DTaP-IPV-HB-Hib Vaccine Administrated Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6</title>
        <description>Antibodies titers of PT and FHA were measured by electrochemiluminescent (ECL) assay.</description>
        <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
        <population>Analysis was performed on PPAS. Data for this outcome measure were not planned to be collected and analyzed for Groups 1, 2, 3, 5, 7, 8, 9, 10, 11, and 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and DTaP-IPV-HB-Hib vaccine on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of DTaP-IPV-HB-Hib vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Pertussis Toxoid (PT) and Filamentous Hemagglutinin (FHA) Antibodies Following Injection With DTaP-IPV-HB-Hib Vaccine Administrated Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6</title>
          <description>Antibodies titers of PT and FHA were measured by electrochemiluminescent (ECL) assay.</description>
          <population>Analysis was performed on PPAS. Data for this outcome measure were not planned to be collected and analyzed for Groups 1, 2, 3, 5, 7, 8, 9, 10, 11, and 12.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PT: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" lower_limit="15.1" upper_limit="21.3"/>
                    <measurement group_id="O2" value="20.4" lower_limit="15.3" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT: Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" lower_limit="130" upper_limit="159"/>
                    <measurement group_id="O2" value="169" lower_limit="144" upper_limit="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FHA: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="37.0" upper_limit="55.9"/>
                    <measurement group_id="O2" value="57.4" lower_limit="41.4" upper_limit="79.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FHA: Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299" lower_limit="265" upper_limit="337"/>
                    <measurement group_id="O2" value="391" lower_limit="319" upper_limit="480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of DTaP-IPV-HB-Hib Antibodies Following Injection With DTaP-IPV-HB-Hib Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6</title>
        <description>Antibodies titers of Diphtheria, Tetanus and Pertussis were measured by ECL assay. Antibodies titers of poliovirus types 1, 2, and 3 were measured by neutralization assay. Antibodies titers of Hepatitis B were measured by an immunodiagnostic system using chemiluminescence detection. Antibodies titers of Polyribosyl-ribitol phosphate (PRP) were measured by Farr-type radioimmunoassay (RIA).</description>
        <time_frame>Day 0 (for tetanus only) and Day 30 post-vaccination</time_frame>
        <population>Analysis was performed on PPAS. Here, ‚ÄòNumber analyzed‚Äô = participants with available data for each specified category. Data for this outcome measure were not planned to be collected and analyzed for Groups 1, 2, 3, 5, 7, 8, 9, 10, 11, and 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and DTaP-IPV-HB-Hib vaccine on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of DTaP-IPV-HB-Hib vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of DTaP-IPV-HB-Hib Antibodies Following Injection With DTaP-IPV-HB-Hib Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6</title>
          <description>Antibodies titers of Diphtheria, Tetanus and Pertussis were measured by ECL assay. Antibodies titers of poliovirus types 1, 2, and 3 were measured by neutralization assay. Antibodies titers of Hepatitis B were measured by an immunodiagnostic system using chemiluminescence detection. Antibodies titers of Polyribosyl-ribitol phosphate (PRP) were measured by Farr-type radioimmunoassay (RIA).</description>
          <population>Analysis was performed on PPAS. Here, ‚ÄòNumber analyzed‚Äô = participants with available data for each specified category. Data for this outcome measure were not planned to be collected and analyzed for Groups 1, 2, 3, 5, 7, 8, 9, 10, 11, and 12.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.52" lower_limit="4.94" upper_limit="6.17"/>
                    <measurement group_id="O2" value="6.34" lower_limit="5.51" upper_limit="7.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.238" lower_limit="0.196" upper_limit="0.289"/>
                    <measurement group_id="O2" value="0.234" lower_limit="0.177" upper_limit="0.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.06" lower_limit="6.01" upper_limit="8.29"/>
                    <measurement group_id="O2" value="7.11" lower_limit="5.79" upper_limit="8.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio 1: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4560" lower_limit="3870" upper_limit="5373"/>
                    <measurement group_id="O2" value="4034" lower_limit="3052" upper_limit="5332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio 2: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7244" lower_limit="6208" upper_limit="8453"/>
                    <measurement group_id="O2" value="5618" lower_limit="4578" upper_limit="6895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio 3: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5977" lower_limit="4958" upper_limit="7205"/>
                    <measurement group_id="O2" value="5100" lower_limit="3840" upper_limit="6772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5171" lower_limit="4104" upper_limit="6515"/>
                    <measurement group_id="O2" value="7308" lower_limit="5135" upper_limit="10401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRP: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.6" lower_limit="39.6" upper_limit="54.9"/>
                    <measurement group_id="O2" value="56.2" lower_limit="41.5" upper_limit="76.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Immune Response Following Injection With DTaP-IPV-HB-Hib Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6</title>
        <description>Immune response for DTaP-IPV-HB-Hib vaccine was defined as: anti-tetanus Ab concentrations: &gt;= 0.01 and 0.1 IU/mL at Day 0 and &gt;= 0.1 and 1.0 IU/mL at Day 30, anti-diphtheria Ab concentrations: &gt;= 0.1 and 1.0 IU/mL, anti-PRP Ab concentrations &gt;= 0.15 and 1.0 microgram per milliliter (mcg/mL), anti-poliovirus types 1, 2, and 3 Ab titers &gt;= 1:8, anti-hepatitis B surface antigen Ab concentrations &gt;= 10 mIU/mL, &gt;= 100 mIU/mL.</description>
        <time_frame>Day 0 (tetanus only) and Day 30 post-vaccination</time_frame>
        <population>Analysis was performed on PPAS. Here, ‚ÄòNumber analyzed‚Äô = participants with available data for each specified category. Data for this outcome measure were not planned to be collected and analyzed for Groups 1, 2, 3, 5, 7, 8, 9, 10, 11 and 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate and DTaP-IPV-HB-Hib vaccine on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of DTaP-IPV-HB-Hib vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Immune Response Following Injection With DTaP-IPV-HB-Hib Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6</title>
          <description>Immune response for DTaP-IPV-HB-Hib vaccine was defined as: anti-tetanus Ab concentrations: &gt;= 0.01 and 0.1 IU/mL at Day 0 and &gt;= 0.1 and 1.0 IU/mL at Day 30, anti-diphtheria Ab concentrations: &gt;= 0.1 and 1.0 IU/mL, anti-PRP Ab concentrations &gt;= 0.15 and 1.0 microgram per milliliter (mcg/mL), anti-poliovirus types 1, 2, and 3 Ab titers &gt;= 1:8, anti-hepatitis B surface antigen Ab concentrations &gt;= 10 mIU/mL, &gt;= 100 mIU/mL.</description>
          <population>Analysis was performed on PPAS. Here, ‚ÄòNumber analyzed‚Äô = participants with available data for each specified category. Data for this outcome measure were not planned to be collected and analyzed for Groups 1, 2, 3, 5, 7, 8, 9, 10, 11 and 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria: Day 30 (&gt;=0.1 IU/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diphtheria: Day 30 (&gt;=1 IU/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="95.4" upper_limit="99.8"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus: Day 0 (&gt;=0.01 IU/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus: Day 0 (&gt;=0.1 IU/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3" lower_limit="74.2" upper_limit="87.1"/>
                    <measurement group_id="O2" value="77.6" lower_limit="65.8" upper_limit="86.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus: Day 30 (&gt;=0.1 IU/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus: Day 30 (&gt;=1 IU/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="94.4" upper_limit="99.6"/>
                    <measurement group_id="O2" value="98.5" lower_limit="92.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio 1: Day 30 (&gt;=8 [1/dilution])</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio 2: Day 30 (&gt;=8 [1/dilution])</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio 3: Day 30 (&gt;=8 [1/dilution])</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B: Day 30 (&gt;=10 mIU/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B: Day 30 (&gt;=100 mIU/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="95.4" upper_limit="99.8"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRP: Day 30 (&gt;=0.15 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRP: Day 30 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Vaccine Response of PT and FHA Antibodies Following Injection With DTaP-IPV-HB-Hib Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6</title>
        <description>Pertussis and FHA vaccine response was defined as: if the pre-vaccination concentration is &lt; 4 * lower limit of quantification (LLOQ is equal to 2), then the post-vaccination concentration is &gt;=4 * pre-vaccination concentration and if the pre-vaccination concentration is &gt;= 4 * LLOQ, then the post-vaccination concentration is &gt;= 2 * pre-vaccination concentration.</description>
        <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
        <population>Analysis was performed on PPAS. Data for this outcome measure were not planned to be collected and analyzed for Groups 1, 2, 3, 5, 7, 8, 9, 10, 11, and 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and DTaP-IPV-HB-Hib vaccine on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of DTaP-IPV-HB-Hib vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Vaccine Response of PT and FHA Antibodies Following Injection With DTaP-IPV-HB-Hib Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6</title>
          <description>Pertussis and FHA vaccine response was defined as: if the pre-vaccination concentration is &lt; 4 * lower limit of quantification (LLOQ is equal to 2), then the post-vaccination concentration is &gt;=4 * pre-vaccination concentration and if the pre-vaccination concentration is &gt;= 4 * LLOQ, then the post-vaccination concentration is &gt;= 2 * pre-vaccination concentration.</description>
          <population>Analysis was performed on PPAS. Data for this outcome measure were not planned to be collected and analyzed for Groups 1, 2, 3, 5, 7, 8, 9, 10, 11, and 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PT: Day 30/Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.0" lower_limit="85.3" upper_limit="95.0"/>
                    <measurement group_id="O2" value="92.6" lower_limit="83.7" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FHA: Day 30/Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.0" lower_limit="83.0" upper_limit="93.5"/>
                    <measurement group_id="O2" value="88.2" lower_limit="78.1" upper_limit="94.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of PCV13 Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F Antibodies Following Injection With PCV13 Vaccine Administrated Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 7 and 9</title>
        <description>Antibodies of pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F were measured by ECL assay.</description>
        <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
        <population>Analysis was performed on PPAS. Here, ‚ÄòNumber analyzed‚Äô = participants with available data for each specified category. Data for this outcome measure were not planned to be collected and analyzed for Groups 1, 2, 3, 4, 5, 6, 8, 10, 11, and 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Russian Federation (Group 7):MenACYW Conjugate + PCV13 Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate vaccine and PCV13 vaccine on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Russian Federation (Group 9): PCV13 Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of PCV13 vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of PCV13 Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F Antibodies Following Injection With PCV13 Vaccine Administrated Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 7 and 9</title>
          <description>Antibodies of pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F were measured by ECL assay.</description>
          <population>Analysis was performed on PPAS. Here, ‚ÄòNumber analyzed‚Äô = participants with available data for each specified category. Data for this outcome measure were not planned to be collected and analyzed for Groups 1, 2, 3, 4, 5, 6, 8, 10, 11, and 12.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.867" lower_limit="0.741" upper_limit="1.01"/>
                    <measurement group_id="O2" value="0.918" lower_limit="0.713" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" lower_limit="1.98" upper_limit="2.75"/>
                    <measurement group_id="O2" value="2.14" lower_limit="1.63" upper_limit="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.409" lower_limit="0.341" upper_limit="0.491"/>
                    <measurement group_id="O2" value="0.414" lower_limit="0.322" upper_limit="0.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.802" lower_limit="0.664" upper_limit="0.967"/>
                    <measurement group_id="O2" value="0.773" lower_limit="0.608" upper_limit="0.983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.604" lower_limit="0.511" upper_limit="0.715"/>
                    <measurement group_id="O2" value="0.653" lower_limit="0.507" upper_limit="0.840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" lower_limit="1.68" upper_limit="2.31"/>
                    <measurement group_id="O2" value="1.49" lower_limit="1.15" upper_limit="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.828" lower_limit="0.719" upper_limit="0.953"/>
                    <measurement group_id="O2" value="0.782" lower_limit="0.610" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" lower_limit="1.70" upper_limit="2.31"/>
                    <measurement group_id="O2" value="1.73" lower_limit="1.33" upper_limit="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" lower_limit="1.33" upper_limit="1.95"/>
                    <measurement group_id="O2" value="1.48" lower_limit="1.09" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.96" lower_limit="4.99" upper_limit="7.13"/>
                    <measurement group_id="O2" value="6.13" lower_limit="4.47" upper_limit="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.895" lower_limit="0.715" upper_limit="1.12"/>
                    <measurement group_id="O2" value="0.691" lower_limit="0.514" upper_limit="0.929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.66" lower_limit="2.99" upper_limit="4.50"/>
                    <measurement group_id="O2" value="2.57" lower_limit="1.83" upper_limit="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" lower_limit="1.12" upper_limit="1.55"/>
                    <measurement group_id="O2" value="1.39" lower_limit="1.08" upper_limit="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" lower_limit="2.59" upper_limit="3.58"/>
                    <measurement group_id="O2" value="2.67" lower_limit="2.05" upper_limit="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.841" lower_limit="0.710" upper_limit="0.997"/>
                    <measurement group_id="O2" value="0.863" lower_limit="0.660" upper_limit="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" lower_limit="1.95" upper_limit="2.81"/>
                    <measurement group_id="O2" value="2.52" lower_limit="1.92" upper_limit="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" lower_limit="2.74" upper_limit="3.86"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.30" upper_limit="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.62" lower_limit="6.56" upper_limit="8.83"/>
                    <measurement group_id="O2" value="6.30" lower_limit="5.00" upper_limit="7.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.737" lower_limit="0.620" upper_limit="0.876"/>
                    <measurement group_id="O2" value="0.995" lower_limit="0.766" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="1.87" upper_limit="2.58"/>
                    <measurement group_id="O2" value="2.21" lower_limit="1.73" upper_limit="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" lower_limit="1.36" upper_limit="2.01"/>
                    <measurement group_id="O2" value="1.96" lower_limit="1.46" upper_limit="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75" lower_limit="4.85" upper_limit="6.80"/>
                    <measurement group_id="O2" value="5.91" lower_limit="4.54" upper_limit="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" lower_limit="1.43" upper_limit="2.21"/>
                    <measurement group_id="O2" value="1.74" lower_limit="1.28" upper_limit="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.58" lower_limit="4.57" upper_limit="6.81"/>
                    <measurement group_id="O2" value="5.53" lower_limit="3.98" upper_limit="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.631" lower_limit="0.519" upper_limit="0.768"/>
                    <measurement group_id="O2" value="0.733" lower_limit="0.537" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" lower_limit="2.04" upper_limit="2.86"/>
                    <measurement group_id="O2" value="2.58" lower_limit="1.98" upper_limit="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Immune Response Following Injection With PCV13 Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 7 and 9</title>
        <description>Immune response for PCV13 for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F was defined as: antibodies concentrations &gt;=0.35 mcg/mL or &gt;=1.0 mcg/mL.</description>
        <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
        <population>Analysis was performed on PPAS. Here, 'Number analyzed' = participants with available data for each specified category. Data for this outcome measure were not planned to be collected and analyzed for Groups 1, 2, 3, 4, 5, 6, 8, 10, 11, and 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Russian Federation (Group 7):MenACYW Conjugate + PCV13 Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate vaccine and PCV13 vaccine on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Russian Federation (Group 9): PCV13 Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of PCV13 vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Immune Response Following Injection With PCV13 Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 7 and 9</title>
          <description>Immune response for PCV13 for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F was defined as: antibodies concentrations &gt;=0.35 mcg/mL or &gt;=1.0 mcg/mL.</description>
          <population>Analysis was performed on PPAS. Here, 'Number analyzed' = participants with available data for each specified category. Data for this outcome measure were not planned to be collected and analyzed for Groups 1, 2, 3, 4, 5, 6, 8, 10, 11, and 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1: Day 0 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" lower_limit="74.6" upper_limit="86.1"/>
                    <measurement group_id="O2" value="79.3" lower_limit="69.6" upper_limit="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1: Day 0 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0" lower_limit="35.9" upper_limit="50.3"/>
                    <measurement group_id="O2" value="45.7" lower_limit="35.2" upper_limit="56.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1: Day 30 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="94.0" upper_limit="99.1"/>
                    <measurement group_id="O2" value="94.6" lower_limit="87.8" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1: Day 30 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4" lower_limit="69.8" upper_limit="82.3"/>
                    <measurement group_id="O2" value="70.7" lower_limit="60.2" upper_limit="79.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: Day 0 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" lower_limit="42.0" upper_limit="56.5"/>
                    <measurement group_id="O2" value="53.3" lower_limit="42.6" upper_limit="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: Day 0 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" lower_limit="16.6" upper_limit="28.8"/>
                    <measurement group_id="O2" value="18.5" lower_limit="11.1" upper_limit="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: Day 30 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3" lower_limit="65.3" upper_limit="78.5"/>
                    <measurement group_id="O2" value="76.1" lower_limit="66.1" upper_limit="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: Day 30 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" lower_limit="40.9" upper_limit="55.5"/>
                    <measurement group_id="O2" value="38.0" lower_limit="28.1" upper_limit="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: Day 0 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8" lower_limit="59.7" upper_limit="73.4"/>
                    <measurement group_id="O2" value="68.5" lower_limit="58.0" upper_limit="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: Day 0 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" lower_limit="27.1" upper_limit="40.8"/>
                    <measurement group_id="O2" value="38.0" lower_limit="28.1" upper_limit="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: Day 30 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" lower_limit="88.0" upper_limit="95.9"/>
                    <measurement group_id="O2" value="90.2" lower_limit="82.2" upper_limit="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: Day 30 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.1" lower_limit="73.7" upper_limit="85.5"/>
                    <measurement group_id="O2" value="62.0" lower_limit="51.2" upper_limit="71.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: Day 0 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3" lower_limit="75.1" upper_limit="86.6"/>
                    <measurement group_id="O2" value="76.1" lower_limit="66.1" upper_limit="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: Day 0 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5" lower_limit="34.4" upper_limit="48.7"/>
                    <measurement group_id="O2" value="50.0" lower_limit="39.4" upper_limit="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: Day 30 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8" lower_limit="90.6" upper_limit="97.5"/>
                    <measurement group_id="O2" value="90.2" lower_limit="82.2" upper_limit="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: Day 30 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.2" lower_limit="64.2" upper_limit="77.5"/>
                    <measurement group_id="O2" value="69.6" lower_limit="59.1" upper_limit="78.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: Day 0 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.2" lower_limit="85.1" upper_limit="94.0"/>
                    <measurement group_id="O2" value="82.6" lower_limit="73.3" upper_limit="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: Day 0 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.7" lower_limit="56.5" upper_limit="70.5"/>
                    <measurement group_id="O2" value="65.2" lower_limit="54.6" upper_limit="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: Day 30 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="94.0" upper_limit="99.1"/>
                    <measurement group_id="O2" value="96.7" lower_limit="90.8" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: Day 30 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="92.6" upper_limit="98.5"/>
                    <measurement group_id="O2" value="90.2" lower_limit="82.2" upper_limit="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: Day 0 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" lower_limit="65.1" upper_limit="78.2"/>
                    <measurement group_id="O2" value="68.5" lower_limit="58.0" upper_limit="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: Day 0 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" lower_limit="37.4" upper_limit="51.9"/>
                    <measurement group_id="O2" value="41.3" lower_limit="31.1" upper_limit="52.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: Day 30 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8" lower_limit="90.6" upper_limit="97.5"/>
                    <measurement group_id="O2" value="92.4" lower_limit="84.9" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: Day 30 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" lower_limit="80.7" upper_limit="90.9"/>
                    <measurement group_id="O2" value="75.0" lower_limit="64.9" upper_limit="83.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: Day 0 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0" lower_limit="81.5" upper_limit="91.4"/>
                    <measurement group_id="O2" value="88.0" lower_limit="79.6" upper_limit="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: Day 0 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" lower_limit="55.5" upper_limit="69.5"/>
                    <measurement group_id="O2" value="65.2" lower_limit="54.6" upper_limit="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: Day 30 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="95.5" upper_limit="99.7"/>
                    <measurement group_id="O2" value="94.6" lower_limit="87.8" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: Day 30 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.1" lower_limit="73.7" upper_limit="85.5"/>
                    <measurement group_id="O2" value="83.7" lower_limit="74.5" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: Day 0 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2" lower_limit="70.6" upper_limit="82.9"/>
                    <measurement group_id="O2" value="79.3" lower_limit="69.6" upper_limit="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: Day 0 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0" lower_limit="34.9" upper_limit="49.3"/>
                    <measurement group_id="O2" value="43.5" lower_limit="33.2" upper_limit="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: Day 30 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" lower_limit="91.2" upper_limit="97.8"/>
                    <measurement group_id="O2" value="92.4" lower_limit="84.9" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: Day 30 (&gt;=1.0 microg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3" lower_limit="67.5" upper_limit="80.4"/>
                    <measurement group_id="O2" value="75.0" lower_limit="64.9" upper_limit="83.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: Day 0 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" lower_limit="92.0" upper_limit="98.2"/>
                    <measurement group_id="O2" value="92.4" lower_limit="84.9" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: Day 0 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="77.3" upper_limit="88.3"/>
                    <measurement group_id="O2" value="87.0" lower_limit="78.3" upper_limit="93.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: Day 30 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="96.3" upper_limit="99.9"/>
                    <measurement group_id="O2" value="98.9" lower_limit="94.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: Day 30 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="94.0" upper_limit="99.1"/>
                    <measurement group_id="O2" value="94.6" lower_limit="87.8" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: Day 0 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5" lower_limit="64.6" upper_limit="77.8"/>
                    <measurement group_id="O2" value="84.8" lower_limit="75.8" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: Day 0 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="33.9" upper_limit="48.2"/>
                    <measurement group_id="O2" value="48.9" lower_limit="38.3" upper_limit="59.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: Day 30 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" lower_limit="91.2" upper_limit="97.8"/>
                    <measurement group_id="O2" value="92.4" lower_limit="84.9" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: Day 30 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1" lower_limit="72.6" upper_limit="84.6"/>
                    <measurement group_id="O2" value="79.3" lower_limit="69.6" upper_limit="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: Day 0 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0" lower_limit="81.5" upper_limit="91.4"/>
                    <measurement group_id="O2" value="87.0" lower_limit="78.3" upper_limit="93.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: Day 0 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" lower_limit="55.5" upper_limit="69.5"/>
                    <measurement group_id="O2" value="69.6" lower_limit="59.1" upper_limit="78.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: Day 30 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="92.6" upper_limit="98.5"/>
                    <measurement group_id="O2" value="98.9" lower_limit="94.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: Day 30 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" lower_limit="88.0" upper_limit="95.9"/>
                    <measurement group_id="O2" value="90.2" lower_limit="82.2" upper_limit="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: Day 0 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0" lower_limit="81.5" upper_limit="91.4"/>
                    <measurement group_id="O2" value="89.1" lower_limit="80.9" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: Day 0 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2" lower_limit="57.0" upper_limit="71.0"/>
                    <measurement group_id="O2" value="65.2" lower_limit="54.6" upper_limit="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: Day 30 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.9" lower_limit="93.3" upper_limit="98.8"/>
                    <measurement group_id="O2" value="97.8" lower_limit="92.4" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: Day 30 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.0" lower_limit="82.5" upper_limit="92.2"/>
                    <measurement group_id="O2" value="85.9" lower_limit="77.0" upper_limit="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: Day 0 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" lower_limit="61.1" upper_limit="74.7"/>
                    <measurement group_id="O2" value="64.1" lower_limit="53.5" upper_limit="73.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: Day 0 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9" lower_limit="28.2" upper_limit="42.1"/>
                    <measurement group_id="O2" value="44.6" lower_limit="34.2" upper_limit="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: Day 30 (&gt;=0.35 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="92.6" upper_limit="98.5"/>
                    <measurement group_id="O2" value="93.5" lower_limit="86.3" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: Day 30 (&gt;=1.0 mcg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3" lower_limit="65.3" upper_limit="78.5"/>
                    <measurement group_id="O2" value="78.3" lower_limit="68.4" upper_limit="86.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 1, 2, 3, 10, 11, and 12</title>
        <description>Solicited Reaction (SR) was defined as an adverse event (AE) that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved or the movement of the injected limb reduced, Erythema and swelling: Grade 3: &gt;= 50 millimeter (mm). Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.</description>
        <time_frame>Within 7 days post vaccination</time_frame>
        <population>Analysis was performed on Safety analysis set (SafAS) which included participants who received at least 1 dose of study vaccine(s) &amp; had any safety data available. Here '0' in the number analyzed field signifies that the vaccines mentioned in the respective categories were not administered to the specified group.</population>
        <group_list>
          <group group_id="O1">
            <title>South Korea(Group1):MenACYW Conjugate +MMR +Varicella Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>South Korea (Group 2): MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>South Korea (Group 3): MMR + Varicella Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Thailand (Group 10):MenACYW Conjugate + MMR +Varicella Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Thailand (Group 11): MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>Thailand (Group 12): MMR +Varicella Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 1, 2, 3, 10, 11, and 12</title>
          <description>Solicited Reaction (SR) was defined as an adverse event (AE) that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved or the movement of the injected limb reduced, Erythema and swelling: Grade 3: &gt;= 50 millimeter (mm). Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.</description>
          <population>Analysis was performed on Safety analysis set (SafAS) which included participants who received at least 1 dose of study vaccine(s) &amp; had any safety data available. Here '0' in the number analyzed field signifies that the vaccines mentioned in the respective categories were not administered to the specified group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MenACYW: Tenderness: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenACYW: Tenderness: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenACYW: Erythema: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenACYW: Erythema: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenACYW: Swelling: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenACYW: Swelling: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR: Tenderness: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR: Tenderness: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR: Erythema: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR: Erythema: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR: Swelling: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR: Swelling: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella: Tenderness: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella: Tenderness: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella: Erythema: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella: Erythema: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella: Swelling: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella: Swelling: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 4, 5, and 6</title>
        <description>SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved or the movement of the injected limb reduced, Erythema and swelling: Grade 3: &gt;= 50 mm. Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.</description>
        <time_frame>Within 7 days post vaccination</time_frame>
        <population>Analysis was performed on SafAS. Here, ‚ÄòNumber analyzed‚Äô = participants with available data for each specified category and '0' in the number analyzed field signifies that the vaccines mentioned in the respective categories were not administered to the specified group.</population>
        <group_list>
          <group group_id="O1">
            <title>Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and DTaP-IPV-HB-Hib vaccine on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Mexico (Group 5): MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of DTaP-IPV-HB-Hib Vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 4, 5, and 6</title>
          <description>SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved or the movement of the injected limb reduced, Erythema and swelling: Grade 3: &gt;= 50 mm. Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.</description>
          <population>Analysis was performed on SafAS. Here, ‚ÄòNumber analyzed‚Äô = participants with available data for each specified category and '0' in the number analyzed field signifies that the vaccines mentioned in the respective categories were not administered to the specified group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MenACYW: Tenderness: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenACYW: Tenderness: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenACYW: Erythema: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenACYW: Erythema: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenACYW: Swelling: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenACYW: Swelling: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DTaP-IPV-HB-Hib: Tenderness: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DTaP-IPV-HB-Hib: Tenderness: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DTaP-IPV-HB-Hib: Erythema: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DTaP-IPV-HB-Hib: Erythema: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DTaP-IPV-HB-Hib: Swelling: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DTaP-IPV-HB-Hib: Swelling: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 7, 8, and 9</title>
        <description>SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved, or the movement of the injected limb reduced, Erythema and swelling: Grade 3: &gt;= 50 mm. Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.</description>
        <time_frame>Within 7 days post vaccination</time_frame>
        <population>Analysis was performed on SafAS. Here, '0' in the number analyzed field signifies that the vaccines mentioned in the respective categories were not administered to the specified group.</population>
        <group_list>
          <group group_id="O1">
            <title>Russian Federation (Group 7):MenACYW Conjugate + PCV13 Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate vaccine and PCV13 vaccine on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Russian Federation (Group 8): MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 14 months or 16 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Russian Federation (Group 9): PCV13 Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of PCV13 Vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 7, 8, and 9</title>
          <description>SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved, or the movement of the injected limb reduced, Erythema and swelling: Grade 3: &gt;= 50 mm. Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.</description>
          <population>Analysis was performed on SafAS. Here, '0' in the number analyzed field signifies that the vaccines mentioned in the respective categories were not administered to the specified group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MenACYW: Tenderness: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenACYW: Tenderness: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenACYW: Erythema: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenACYW: Erythema: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenACYW: Swelling: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenACYW: Swelling: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCV13: Tenderness: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCV13: Tenderness: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCV13: Erythema: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCV13: Erythema: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCV13: Swelling: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCV13: Swelling: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting at Least One Solicited Systemic Reactions (Fever, Vomiting, Abnormal Crying, Drowsiness, Appetite Loss, and Irritability)</title>
        <description>SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited systemic reaction: Fever: Grade 3: &gt; 39.5 degree Celsius, Vomiting: Grade 3: &gt;= 6 episodes per 24 hours or requiring parenteral hydration, Crying abnormal: Grade 3: &gt; 3 hours, Drowsiness: Grade 3: sleeping most of the time or difficult to wake up, Appetite lost: Grade 3: refuses &gt;= 3 feeds/meals or refuses most feeds/meals, Irritability: Grade 3: inconsolable. Participants with any of the Grade and Grade 3 solicited systemic reactions were reported.</description>
        <time_frame>Within 7 days post vaccination</time_frame>
        <population>Analysis was performed on Safety analysis set. Here, ‚ÄòOverall number of participants analyzed‚Äô = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>South Korea(Group1):MenACYW Conjugate +MMR +Varicella Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>South Korea (Group 2): MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>South Korea (Group 3): MMR + Varicella Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Thailand (Group 10):MenACYW Conjugate + MMR +Varicella Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Thailand (Group 11): MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>Thailand (Group 12): MMR + Varicella Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.</description>
          </group>
          <group group_id="O7">
            <title>Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and DTaP-IPV-HB-Hib vaccine on Day 0.</description>
          </group>
          <group group_id="O8">
            <title>Mexico (Group 5): MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
          <group group_id="O9">
            <title>Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of DTaP-IPV-HB-Hib Vaccine on Day 0.</description>
          </group>
          <group group_id="O10">
            <title>Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate vaccine and PCV13 vaccine on Day 0.</description>
          </group>
          <group group_id="O11">
            <title>Russian Federation (Group 8): MenACYW Conjugate Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 14 months or 16 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
          </group>
          <group group_id="O12">
            <title>Russian Federation (Group 9): PCV13 Vaccine</title>
            <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of PCV13 vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least One Solicited Systemic Reactions (Fever, Vomiting, Abnormal Crying, Drowsiness, Appetite Loss, and Irritability)</title>
          <description>SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited systemic reaction: Fever: Grade 3: &gt; 39.5 degree Celsius, Vomiting: Grade 3: &gt;= 6 episodes per 24 hours or requiring parenteral hydration, Crying abnormal: Grade 3: &gt; 3 hours, Drowsiness: Grade 3: sleeping most of the time or difficult to wake up, Appetite lost: Grade 3: refuses &gt;= 3 feeds/meals or refuses most feeds/meals, Irritability: Grade 3: inconsolable. Participants with any of the Grade and Grade 3 solicited systemic reactions were reported.</description>
          <population>Analysis was performed on Safety analysis set. Here, ‚ÄòOverall number of participants analyzed‚Äô = participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="191"/>
                <count group_id="O8" value="98"/>
                <count group_id="O9" value="95"/>
                <count group_id="O10" value="200"/>
                <count group_id="O11" value="100"/>
                <count group_id="O12" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="32"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="16"/>
                    <measurement group_id="O10" value="12"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal crying: Any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="46"/>
                    <measurement group_id="O8" value="25"/>
                    <measurement group_id="O9" value="26"/>
                    <measurement group_id="O10" value="8"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal crying: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness: Any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="31"/>
                    <measurement group_id="O8" value="15"/>
                    <measurement group_id="O9" value="17"/>
                    <measurement group_id="O10" value="25"/>
                    <measurement group_id="O11" value="6"/>
                    <measurement group_id="O12" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite Lost: Any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="51"/>
                    <measurement group_id="O8" value="25"/>
                    <measurement group_id="O9" value="20"/>
                    <measurement group_id="O10" value="19"/>
                    <measurement group_id="O11" value="12"/>
                    <measurement group_id="O12" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite Lost: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="64"/>
                    <measurement group_id="O8" value="34"/>
                    <measurement group_id="O9" value="33"/>
                    <measurement group_id="O10" value="26"/>
                    <measurement group_id="O11" value="16"/>
                    <measurement group_id="O12" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE data were collected from Day 0 up to Day 30 post-vaccination. SR data were collected within 7 days after vaccination. Serious adverse event (SAE) data were collected throughout the study period (up to Day 30 post-vaccination).</time_frame>
      <desc>SR: an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the eCRF (i.e., solicited) in terms of symptom and/or onset post-vaccination. Analysis was done on SafAS. In the AE section, solicited reactions Fever, Abnormal crying, Drowsiness, and Appetite lost are reported under Pyrexia, Crying, Somnolence, and Decreased Appetite, respectively.</desc>
      <group_list>
        <group group_id="E1">
          <title>South Korea(Group1):MenACYW Conjugate +MMR +Varicella Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.</description>
        </group>
        <group group_id="E2">
          <title>South Korea (Group 2): MenACYW Conjugate Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
        </group>
        <group group_id="E3">
          <title>South Korea (Group 3): MMR + Varicella Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.</description>
        </group>
        <group group_id="E4">
          <title>Thailand (Group 10):MenACYW Conjugate + MMR +Varicella Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.</description>
        </group>
        <group group_id="E5">
          <title>Thailand (Group 11): MenACYW Conjugate Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
        </group>
        <group group_id="E6">
          <title>Thailand (Group 12): MMR + Varicella Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.</description>
        </group>
        <group group_id="E7">
          <title>Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and DTaP-IPV-HB-Hib vaccine on Day 0.</description>
        </group>
        <group group_id="E8">
          <title>Mexico (Group 5): MenACYW Conjugate Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
        </group>
        <group group_id="E9">
          <title>Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 23 months) received single dose of DTaP-IPV-HB-Hib Vaccine on Day 0.</description>
        </group>
        <group group_id="E10">
          <title>Russian Federation (Group 7):MenACYW Conjugate + PCV13 Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate and PCV13 Vaccine on Day 0.</description>
        </group>
        <group group_id="E11">
          <title>Russian Federation (Group 8): MenACYW Conjugate Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 12 to 14 months or 16 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.</description>
        </group>
        <group group_id="E12">
          <title>Russian Federation (Group 9): PCV13 Vaccine</title>
          <description>Healthy, meningococcal-vaccine na√Øve toddlers (aged 15 to 23 months) received single dose of PCV13 Vaccine on Day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Bronchitis Viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Croup Infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hand-Foot-And-Mouth Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Otitis Media Viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pneumonia Viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Respiratory Syncytial Virus Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="142" subjects_at_risk="200"/>
                <counts group_id="E8" subjects_affected="65" subjects_at_risk="100"/>
                <counts group_id="E9" subjects_affected="85" subjects_at_risk="100"/>
                <counts group_id="E10" subjects_affected="75" subjects_at_risk="200"/>
                <counts group_id="E11" subjects_affected="30" subjects_at_risk="100"/>
                <counts group_id="E12" subjects_affected="17" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="13" subjects_affected="12" subjects_at_risk="200"/>
                <counts group_id="E8" events="6" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E9" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Vomiting events that occurred after 7 days post-vaccination were considered as unsolicited AE.</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E7" events="17" subjects_affected="16" subjects_at_risk="200"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E9" events="9" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <description>Crying/Abnormal crying events that occurred after 7 days post-vaccination were considered as unsolicited AE.</description>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="103"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="86"/>
                <counts group_id="E5" events="17" subjects_affected="17" subjects_at_risk="42"/>
                <counts group_id="E6" events="12" subjects_affected="12" subjects_at_risk="42"/>
                <counts group_id="E7" events="46" subjects_affected="46" subjects_at_risk="200"/>
                <counts group_id="E8" events="25" subjects_affected="25" subjects_at_risk="100"/>
                <counts group_id="E9" events="26" subjects_affected="26" subjects_at_risk="100"/>
                <counts group_id="E10" events="8" subjects_affected="8" subjects_at_risk="200"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" events="60" subjects_affected="35" subjects_at_risk="103"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="52"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E4" events="71" subjects_affected="36" subjects_at_risk="86"/>
                <counts group_id="E5" events="13" subjects_affected="13" subjects_at_risk="42"/>
                <counts group_id="E6" events="23" subjects_affected="16" subjects_at_risk="42"/>
                <counts group_id="E7" events="96" subjects_affected="67" subjects_at_risk="200"/>
                <counts group_id="E8" events="15" subjects_affected="15" subjects_at_risk="100"/>
                <counts group_id="E9" events="37" subjects_affected="37" subjects_at_risk="100"/>
                <counts group_id="E10" events="91" subjects_affected="55" subjects_at_risk="200"/>
                <counts group_id="E11" events="17" subjects_affected="17" subjects_at_risk="100"/>
                <counts group_id="E12" events="8" subjects_affected="8" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="72" subjects_affected="31" subjects_at_risk="103"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="52"/>
                <counts group_id="E3" events="21" subjects_affected="12" subjects_at_risk="53"/>
                <counts group_id="E4" events="63" subjects_affected="31" subjects_at_risk="86"/>
                <counts group_id="E5" events="17" subjects_affected="17" subjects_at_risk="42"/>
                <counts group_id="E6" events="32" subjects_affected="19" subjects_at_risk="42"/>
                <counts group_id="E7" events="148" subjects_affected="87" subjects_at_risk="200"/>
                <counts group_id="E8" events="27" subjects_affected="27" subjects_at_risk="100"/>
                <counts group_id="E9" events="54" subjects_affected="54" subjects_at_risk="100"/>
                <counts group_id="E10" events="62" subjects_affected="37" subjects_at_risk="200"/>
                <counts group_id="E11" events="8" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E12" events="9" subjects_affected="9" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" events="35" subjects_affected="25" subjects_at_risk="103"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="52"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E4" events="38" subjects_affected="18" subjects_at_risk="86"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E6" events="9" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E7" events="68" subjects_affected="52" subjects_at_risk="200"/>
                <counts group_id="E8" events="8" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E9" events="30" subjects_affected="30" subjects_at_risk="100"/>
                <counts group_id="E10" events="27" subjects_affected="21" subjects_at_risk="200"/>
                <counts group_id="E11" events="7" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Pyrexia/Fever events that occurred after 7 days post-vaccination were considered as unsolicited AE.</description>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="103"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E7" events="35" subjects_affected="35" subjects_at_risk="200"/>
                <counts group_id="E8" events="8" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E9" events="17" subjects_affected="17" subjects_at_risk="100"/>
                <counts group_id="E10" events="13" subjects_affected="13" subjects_at_risk="200"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="37" subjects_affected="29" subjects_at_risk="103"/>
                <counts group_id="E2" events="23" subjects_affected="17" subjects_at_risk="52"/>
                <counts group_id="E3" events="18" subjects_affected="13" subjects_at_risk="53"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E7" events="31" subjects_affected="29" subjects_at_risk="200"/>
                <counts group_id="E8" events="18" subjects_affected="18" subjects_at_risk="100"/>
                <counts group_id="E9" events="16" subjects_affected="15" subjects_at_risk="100"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E7" events="9" subjects_affected="9" subjects_at_risk="200"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="200"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="103"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="86"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="42"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E7" events="51" subjects_affected="51" subjects_at_risk="200"/>
                <counts group_id="E8" events="25" subjects_affected="25" subjects_at_risk="100"/>
                <counts group_id="E9" events="20" subjects_affected="20" subjects_at_risk="100"/>
                <counts group_id="E10" events="19" subjects_affected="19" subjects_at_risk="200"/>
                <counts group_id="E11" events="12" subjects_affected="12" subjects_at_risk="100"/>
                <counts group_id="E12" events="7" subjects_affected="7" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="103"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E7" events="31" subjects_affected="31" subjects_at_risk="200"/>
                <counts group_id="E8" events="15" subjects_affected="15" subjects_at_risk="100"/>
                <counts group_id="E9" events="17" subjects_affected="17" subjects_at_risk="100"/>
                <counts group_id="E10" events="25" subjects_affected="25" subjects_at_risk="200"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="103"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="86"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E6" events="14" subjects_affected="14" subjects_at_risk="42"/>
                <counts group_id="E7" events="64" subjects_affected="64" subjects_at_risk="200"/>
                <counts group_id="E8" events="34" subjects_affected="34" subjects_at_risk="100"/>
                <counts group_id="E9" events="33" subjects_affected="33" subjects_at_risk="100"/>
                <counts group_id="E10" events="26" subjects_affected="26" subjects_at_risk="200"/>
                <counts group_id="E11" events="16" subjects_affected="16" subjects_at_risk="100"/>
                <counts group_id="E12" events="9" subjects_affected="9" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="200"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi Pasteur</organization>
      <phone>800-633-1610 ext 1#</phone>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

